

## Synthesis &amp; Evaluation of isoxazole for their antimicrobial activity

Sagar Pol<sup>1,\*</sup>, Vilasrao Kadam<sup>2</sup>, B. Ramesh<sup>3</sup>, Sachin S. Mali<sup>4</sup>, Vijay Patil<sup>5</sup><sup>1,2,5</sup>Bharati Vidyapeeth Institute of Pharmacy, CBD Belapur Navi Mumbai, Maharashtra, <sup>3</sup>SAC College of Pharmacy, BG Nagara, Karnataka, <sup>4</sup>Adarsh Institute of Pharmacy, Vita, Maharashtra**\*Corresponding Author:**

Email: sachinmali143@gmail.com, sagar.pol007@gmail.com

**Abstract**


Isoxazole is five membered heterocyclic ring having a broad spectrum of pharmacological activities like anti-tubercular, anti-cancer, anti-bacterial, anti-fungal, anti-HIV, anti-inflammatory and anti-hypertensive activities.

In the present research work we reported the synthesis of some novel isoxazoles by using various different substituted chalcones and screened for their anti-microbial activity.

**Keyword:** Isoxazole, Anti-microbial activity.**Introduction**

Nitrogen containing heterocycles with an oxygen atom are considered as an important class of compounds in medicinal chemistry because of their diversified biological applications. The exploitation of a simple molecule with different functionalities for the synthesis of heterocycles is a worthwhile contribution in the chemistry of heterocycles.

Isoxazole is a five membered heterocyclic compound containing oxygen and nitrogen atoms in the 1, 2 positions, its partially saturated analogs are called isoxazolines and completely saturated analog is isoxazolidine.



Isoxazoles are an important class of heterocycles, which are largely employed in the area of pharmaceuticals and therapeutics such as insecticidal, antibacterial, antibiotic, antitumour, antifungal, antituberculosis, anticancer and ulcerogenic. Isoxazole derivatives are used in the market as COX-2 inhibitor and anti-inflammatory drugs.

Although isoxazole derivatives have been known for more than 80 years, the investigation of their chemistry commended rather slowly. Earlier studies were mainly devoted to the development of synthetic methods. Recently the attention was focused on the


investigation of chemical properties and in particular on the peculiarities of the behaviour of isoxazole derivatives and the elucidation of their physicochemical characteristics. This enabled new data to be obtained that were considerable importance.

**Materials and Methods**


All the melting points were determined on Micro-controller based melting point apparatus CL 725/726 and were uncorrected. Chloro and nitro benzaldehydes were purchased from Techno chemicals, Bangalore. Other chemicals like hydroxyl amine hydrochloride & sodium acetate were purchased from S.D. Fine chemicals, Bangalore. Silica gel G plates (3x8cm) were used for TLC and spots were located by UV or in iodine chamber. The IR spectra (KBr) were determined on FTIR 8400S, SHIMADZU Spectrometer and the values were expressed in cm<sup>-1</sup> 1H-NMR were recorded in either CDCl<sub>3</sub> or DMSO-d<sub>6</sub> solvents using TMS as an internal reference standard at IIT Chennai and II Sc Bangalore.

**General procedure for synthesis of chalcones and cyclization**

**Step I:** Equimolar quantities of different substituted aromatic benzaldehyde (0.01mol) and substituted aromatic acetophenones (0.01mol) were dissolved in 25 mL of alcohol. Sodium hydroxide solution (0.02mol) was added slowly and the mixture stirred for 12 hr. until the entire mixture becomes very cloud. Then the mixture was poured slowly into 400 mL. of water with constant stirring and kept refrigerator for 24hr. Then precipitate obtained was filtered. Washed and recrystallised from ethanol.



**Step II:** 0.015 mol of chalcone, 0.015mol of hydroxyl ammonium hydrochloride and sodium acetate 0.015mol in 25 mL of ethanol was refluxed for 6hr. The mixture was concentrated by distilling out the solvent under reduced pressure and poured into ice cold water. The precipitate obtained was filtered, washed and recrystallized from acetone.



**N1: 1-(4-nitrophenyl)-3-(4-methoxyphenyl)prop-2-en-1-one**

Yellow Colour crystals, **yield:** 65%, **MP:** 155°C, **FTIR (KBr):** 1657 (C=C), 1573 (C=N), 2855 (C-H), 1031 (C-O) 1440 (R-NO<sub>2</sub>). **<sup>1</sup>H NMR (DMSO):** 3.8-4 (s, CH<sub>3</sub>), 6.7-8.3(m, Ar-H, 8H, CH, 1H). **MS:** m/z (%) 296.09 (57%)[M<sup>+</sup>]. [Found: C.64.86, H.4.08, N.9.45, O.21.60 C<sub>16</sub>H<sub>12</sub>N<sub>2</sub>O<sub>4</sub> requires C.64.83, H.4.03, N. 9.35%].

**N2: 1-(4-nitrophenyl)-3-(4nitrophenyl)prop-2-en-1-one**

Brown Colour crystals, **yield:** 60% , **MP:** 185°C, **FTIR (KBr):** 1595 (C=C) , 1597 (C=N), 1711.33 (C-O), 1456 (R-NO<sub>2</sub>).[Found: C.57.88,H.2.91, N.13.50, O.25.70 C<sub>15</sub>H<sub>9</sub>N<sub>2</sub>O<sub>5</sub> requires C.57.82,H.2.88,N.13.45%].

**N3: 1-(4-nitrophenyl)-3-(3-nitrophenyl)prop-2-en-1-one**

Colourless crystal, **yield:** 62%, **MP:** 160°C, **FTIR (KBr):** 1649(C=C),1593(C=N),2967 (C-H),1100(C-O) 1374 (R-NO<sub>2</sub>).[Found:C.52.20,H.2.63,N.8.12,O.13.91 C<sub>15</sub>H<sub>9</sub>N<sub>2</sub>O<sub>5</sub> requires C.52.18,H.2.60,N.8.10%].

**N4: 1-(4-nitrophenyl)-3-(4-bromophenyl)prop-2-en-1-one**

Pale Brown crystal, **yield:** 50%, **MP:** 169°C, **FTIR (KBr):** 1597(C=C),1527(C=N),3191 (C-H),1101(C-O), 1494 (R-NO<sub>2</sub>),692 (C-Br).[Found: C.52.20,H.2.63,Br.23.15,N.8.12,O.13.91 C<sub>15</sub>H<sub>9</sub>N<sub>2</sub>O<sub>3</sub>Br requires C.52.22,H.2.59,N.8.14%].

**N5: 1-(4-nitrophenyl)-3-(4-chlorophenyl)prop-2-en-1-one**

Brown Colour crystal, **yield:** 60%, **MP:** 156°C,**FTIR (KBr):** 1518(C=C),1622(C=N),3150 (C-H),1015(C-O), 1447 (R-NO<sub>2</sub>),693(C-Cl).[Found: C.59.91,H.3.02,Cl.11.29,N.9.32,O.15.96 C<sub>15</sub>H<sub>9</sub>N<sub>2</sub>O<sub>3</sub>Cl requires C.59.89,H.3.09,N.9.34%].

**N6: 1-(4-nitrophenyl)-1-(4-Phenol)prop-2-en-1-one**

Brown Colour crystal, **yield:** 62%, **MP:** 155°C, **FTIR (KBr):** 1515(C=C),1688(C=N),2954 (C-H),1009(C-O),3254(C-OH).[Found: C.63.83,H.3.57, N.9.92,O.22.67 C<sub>15</sub>H<sub>9</sub>N<sub>2</sub>O<sub>3</sub> requires C.63.80,H.3.54,N.9.94%].

**N7: 1-(4-nitrophenyl)-3-(3-phenol)prop-2-en-1-one**

Brown Colour crystal, **yield:** 65%, **MP:** 170°C, **FTIR (KBr):** 1578(C=C), 1672(C=N),2927 (C-H),1100(C-O), 1390(R-NO<sub>2</sub>),3218(C-OH).[Found: C.63.83,H.3.57,N.9.92,O.22.67 C<sub>15</sub>H<sub>10</sub>N<sub>2</sub>O<sub>3</sub> requires C.63.80,H.3.54,N.9.94%].

**N8: 1-(4-nitrophenyl)-3-(3-methoxyphenyl)prop-2-en-1-one**

Yellow Colour crystal, **yield:** 62%, **MP:** 160°C, **FTIR (KBr):** 1494(C=C),2959(C-H),1036(C-O), 1397.[Found: C.64.86,H.4.08,N.9.45,O.21.60 C<sub>16</sub>H<sub>12</sub>N<sub>2</sub>O<sub>4</sub> requires C.64.84,H.4.04,N.9.44%].

**N9: 1-(4-nitrophenyl)-3-(4-(dimethylamino)phenyl)prop-2-en-1-one**

Brown Colour crystal, **yield:** 72%, **MP:** 178°C, **FTIR (KBr):** 1519(C=C),1647(C=N),2911.19 (C-H),1066(C-O),1519(R-NO<sub>2</sub>). **<sup>1</sup>H NMR (DMSO):** 2.77(s, CH<sub>3</sub>), 6.7-8.4(m, Ar-H,CH,1H).

**MS:**m/z(%)309(57%)[M<sup>+</sup>].[Found:C.68.34,H.5.06,N.9.38,O.5.36C<sub>17</sub>H<sub>15</sub>N<sub>3</sub>O<sub>3</sub>requires C.68.30,H.5.02,N.9.34%].

**C1: 3-(4-chlorophenyl)-5-(4-methoxyphenyl)isoxazole**

Yellow Colour crystal, **yield:** 50%, **MP:** 110°C, **FTIR (KBr):** 1509(C=C),1654(C=N),2965(C-H),1029(C-O),739(C-Cl).[Found:C.67.26,H.4.23,N.4.90,O.11.20,Cl.12.41C<sub>16</sub>H<sub>12</sub>NO<sub>2</sub>Clrequires C.67.30,H.4.22,N.4.89%].

**C2: 3-(4-chlorophenyl)-5-(4-nitrophenyl)isoxazole**

Colourless crystal, **yield:** 60%, **MP:** 90°C, **FTIR (KBr):** 1519(C=C),1637(C=N),3295(Ar-C-H),1012(C-O),750(C-Cl).[Found:C.59.91,H.3.02,N.9.32,O.15.96,Cl.11.79C<sub>15</sub>H<sub>9</sub>N<sub>2</sub>O<sub>5</sub>Clrequires C.59.89,H.3.05,N.9.30%].

**C3: 3-(4-chlorophenyl)-5-(3-nitrophenyl)isoxazole**

**C4: 5-(4-bromophenyl)-3-(4chlorophenyl)isoxazole**

**C5: 3,5-bis(4-chlorophenyl)isoxazole**

**C6: 4-[3-(4-chlorophenyl)isoxazol-5-yl]phenol**

**C7: 3-[3-(4-chlorophenyl)isoxazol-5-yl]phenol**

**C8: 3-(4-chlorophenyl)-5-(3-methoxyphenyl)isoxazole**

**C9: 4-[3-(4-chlorophenyl)isoxazol-5-yl]-N,N-dimethylaniline**

### Methodology

Equimolar quantities of aromatic aldehydes and aromatic acetophenones were dissolved in 25 mL of alcohol. Sodium hydroxide solution (0.02 mol) was added slowly and the mixture stirred for 12 hr. until the entire mixture becomes very cloud. Then the mixture was poured slowly into 400 mL of water with a constant stirring and kept in refrigerator for 24 hr. Then precipitate obtained was filtered, washed and recrystallized from ethanol.

A mixture of chalcone hydroxylamine hydrochloride (0.02 mol) and sodium acetate (0.02 mol) in ethanol (25 mL) was refluxed for 6 hr. The mixture was concentrated by distilling out the solvent under reduced pressure and poured into ice water. The precipitate obtained was filtered, washed and recrystallized from acetone.

**Experimental Section:** All the melting points were determined on Micro-controller based melting point apparatus CL 725/726 and were uncorrected. Chloro and nitro benzaldehydes were purchased from Techno chemicals, Bangalore. Other chemicals like hydroxyl amine hydrochloride & sodium acetate were purchased from S.D. Fine chemicals, Bangalore. Silica gel G plates (3x8cm) were used for TLC and spots were located by UV or in iodine chamber. The IR spectra (KBr) were determined on FTIR 8400S, SHIMADZU Spectrometer and the values were expressed in cm<sup>-1</sup> <sup>1</sup>H-NMR were recorded in either CDCl<sub>3</sub> or DMSO-d<sub>6</sub> solvents using

TMS as an internal reference standard at IIT Chennai and IISc Bangalore.

### Biological Activity

**Antibacterial activity:**<sup>(21-29)</sup> The successive isoxazole derivatives were tested for antibacterial activity systematically against four different strains of bacteria (gram-positive and gram negative) by the agar cup and plate method.

Generally, the antibacterial activity of a compound is expressed in terms of its ability to inhibit the growth of bacteria in nutrient broth or agar; the bacterial inhibition can be measured by two methods: one is the serial dilution method and the other is diffusion method. The serial dilution method is very much useful for the determination of the antibacterial activity. But it is not much useful for the qualitative detection tests and also for the evaluation of a large number of compounds. Therefore, in this investigation the latter is employed. Further, the contemplated agar diffusion method is of three types: (i) Cup-plate method (disc method), (ii) Filter paper strip method, and (iii) Gradient plate method.


The specific method adopted in the present investigation was cup-plate method involving discs of standard diameter, the nutrient agar medium and containing standard bacterial inoculum. The test compounds were introduced into the discs and the diameters of the zones of inhibition were measured. All the derivatives were evaluated for antibacterial activity against, *Escherichia coli*, *Pseudomonas aeruginosa*, *Klebsiella*, *Staphylococcus aureus* following the agar diffusion method.

- The organisms were sub-cultured using nutrient agar medium. The tubes containing sterilized medium were inoculated with respective bacterial strain. Stock cultures were maintained. Bacterial inoculum was prepared by transferring a loop full of stock culture to nutrient broth (100 mL) in a clean sterilized conical flask (250 mL).
- The flasks were incubated at 37 ± 1°C for 18 h before the experimentation. Solutions of the compounds were prepared by dissolving 10 mg of each in 1 mL DMSO.
- Reference standard for gram-positive and gram-negative bacteria were made by dissolving accurately weighed quantity of ciprofloxacin, respectively in DMSO solution, separately. The nutrient agar medium was sterilized by autoclaving at 121°C (15 lb/sq. inch).
- The petri-plates, tubes and flasks plugged with cotton were sterilized in hot air-oven at 160°C for an hour. Into each sterilized petri-plate (10cm diameter), about 30 ml each of molten nutrient bacteria (6 mL of inoculum to 300 mL of nutrient agar medium) was transferred, aseptically.
- The plates were left at room temperature to allow the solidification. In each plate, four wells of 6 mm


diameter were made with a sterile borer. Then, 0.1 ml of the test solution was added to the discs, aseptically and labelled, accordingly. The plates were kept undisturbed for at least 2 h at room temperature to allow diffusion of the solution properly, into nutrient 2 h. at room temperature to allow diffusion of the solution properly, into nutrient agar medium.

- After incubation of the plates at  $37 \pm 1^\circ\text{C}$  for 24 h. the diameter of the zone of inhibition surrounding each of the discs was measured with the help of an 'antibiotic zone reader. All the experiments were carried out in triplicate. Simultaneously, controls were maintained employing 0.1 ml of methanol to observe the solvent effects.


Mean zone of inhibition is including disc diameter: Disc diameter is 6 mm



**N<sub>5</sub> Staphylococcus aureus N<sub>7</sub> Klebsiella Pneumoniae**



**N<sub>9</sub> Klebsiella Pneumoniae C<sub>4</sub> Staphylococcus aureus**



**Table 1: Antibacterial activity of Isoxazole derivatives at different concentration by well diffusion method (values in mm)**

Compound code	Mean zone of inhibition (in mm)															
	S .Aureus				E. coli				P. Auruginosa				Klebsiella			
	100 µg/ml	200 µg/ml	400 µg/ml	500 µg/ml	100 µg/ml	200 µg/ml	400 µg/ml	500 µg/ml	100 µg/ml	200 µg/ml	400 µg/ml	500 µg/ml	100 µg/ml	200 µg/ml	400 µg/ml	500 µg/ml
Standard Ciprofloxacin	8	11	14	18	26	28	30	31	30	31	31	34	26	30	32	34
N <sub>1</sub>	-	-	-	-	8	11	13	16	-	-	-	-	9	10	12	14
N <sub>2</sub>	-	-	-	-	-	-	-	-	-	-	-	17	9	12	16	18
N <sub>3</sub>	8	8	10	11	-	-	-	-	-	-	-	-	-	-	-	-
N <sub>4</sub>	-	-	-	-	-	-	-	-	-	12	14	15	8	10	12	14
N <sub>5</sub>	7	9	11	14	-	-	-	-	-	-	-	-	10	12	14	15
N <sub>6</sub>	-	-	-	-	-	-	-	-	7	9	11	12	8	10	11	12
N <sub>7</sub>	-	-	-	-	-	-	-	-	-	-	-	-	9	12	15	16
N <sub>8</sub>	5	7	7	8	-	-	-	-	-	-	-	-	-	8	11	15
N <sub>9</sub>	-	-	-	-	9	11	13	13	9	12	14	15	11	14	16	18
C <sub>1</sub>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C <sub>2</sub>	8	10	13	16	-	-	-	-	7	9	10	14	-	-	-	-
C <sub>3</sub>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C <sub>4</sub>	9	10	12	16	-	-	-	-	-	-	-	-	10	11	13	15
C <sub>5</sub>	5	6	6	7	-	-	-	-	-	-	-	-	6.5	7	9	11
C <sub>6</sub>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C <sub>7</sub>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C <sub>8</sub>	-	-	-	-	8	10	11	12	-	-	-	-	10	14	16	18

**Table 2: Lipophilicity of isoxazole derivatives compounds 1-18**

Sr. No.	Compound code	logP <sub>10</sub>
1	N <sub>1</sub>	4.27
2	N <sub>2</sub>	3.91
3	N <sub>3</sub>	3.89
4	N <sub>4</sub>	4.83
5	N <sub>5</sub>	5.04
6	N <sub>6</sub>	3.86
7	N <sub>7</sub>	3.84
8	N <sub>8</sub>	4.24
9	N <sub>9</sub>	4.31
10	C <sub>1</sub>	5.37
11	C <sub>2</sub>	5.04
12	C <sub>3</sub>	5.06
13	C <sub>4</sub>	5.69
14	C <sub>5</sub>	5.83
15	C <sub>6</sub>	4.76
16	C <sub>7</sub>	4.75
17	C <sub>8</sub>	5.35
18	C <sub>9</sub>	4.92

### Summary and Conclusion

Isoxazole have played crucial role in the history of heterocyclic chemistry and been extensively important pharmacophores and synthons in the field of organic chemistry owing to their versatile chemotherapeutic importance, a significant amount of research effort has been focused on these nuclei. Isoxazole is a five membered heterocyclic ring system containing oxygen and nitrogen atoms have been reported to possess anthelmintic, antibacterial, antihyperglycemic, analgesic, anti-inflammatory, antipyretic, antiviral and antitumor properties.

In present study we fused the two moieties (aromatic substituted ketone and aromatic substituted aldehyde) to isoxazole with the view to get good pharmacological activity and less toxicity.

As expected, isoxazole derivatives exhibited both anti-bacterial activities in which some compounds are good and some are moderately active like standard employed for comparison. The antibacterial activity which has done on some gram-positive and gram negative showed that few compounds were exhibiting the antibacterial activity by observing zone of inhibition.

Further the detailed structural activity relationship studies are required along with the molecular manipulation i.e. molecular modeling may give better drugs. Molecules prepared for the biological testing do not always turn out as potential new drugs, but may be intended to serve as models for evaluation of hypothesis.

The compound N1 has Isoxazole nucleus with groups OCH<sub>3</sub> at position R1 and NO<sub>2</sub> at R4 also showed enhancement in anti-bacterial activity.

In the compound N9 substitution of R1 of dimethyl amino and NO<sub>2</sub> at R4 position of the aromatic ring also

resulted in an enhancement of anti-bacterial activity. In the compound C4, C9 substitution Br and N(CH<sub>3</sub>)<sub>3</sub> at R1 position and Cl at R4 also showed significant anti-bacterial activity.

Hence in the present study, the aromatic substituted ketone and aromatic substituted aldehydes when linked with isoxazole moiety showed highly potent, more specific antibacterial activity.

### Reference

1. Claisen L, Lowmann O. Studies on introduction isoxazole. *Chem Ber* 1888;21:1149.
2. Ashutosh K. Medicinal Chemistry. New Delhi. New Age Publishers; 2007:95110.
3. Vijay KT, Narasimha G, Ranga B, Rajendra PY. Synthesis, characterization and biological activities of some new pyrimidines and isoxazoles bearing benzofuran moiety. *Int J ChemTech Res* 2010;2(3):1434-40.
4. Rajput AP, Girase PD. Synthesis, Characterisation and microbial screening of isoxazole derivatives of 2,6-dichloro-1-(N-substituted phenyl)-1,4-dihydropyridine 3,5-dicarbaldehyde. *Int J Chem Tech Res* 2011;2(4):0976-5689.
5. Julia K, Renee P, Daniele C, Jean CF. *Bioorg Med Chem*, 2006;14(12): 4067-77.
6. Rajendra PY, Rajasekhar KK, Shankarananth V, Pradeep kumar GSS, Harish reddy G, Rajeevreddy B. Synthesis and antimicrobial activity of 3,5-diaryl isoxazole derivatives. *J Pharm Res* 2010;3(11):2769-71.
7. Madhavi K, Bharathi K, Prasad K. Synthesis and evaluation of 3-methyl-4-nitro-5-(substitutedstyryl) isoxazoles for antioxidant and anti-inflammatory activities. *Res J Pharm Biolo Chem Sci* 2010;1(4):1073.
8. Kalirajan R, Sivakumar SU, Jubie S, Gowramma B, Suresh B. Synthesis and Biological evaluation of some heterocyclic derivatives of Chalcones. *Int J Chem Tech Res* 2009;1:27-34.
9. Anjan K, Sradhasini R, Panda CS, Raju MBV. Synthesis and biological evaluation of 3,5-diarylisoxazoles as antibacterial, antifungal and anti-inflammatory agents. *J Adv Pharma Res* 2011;2(2):94-100.
10. Rajanarendar E, Karunakar D, Srinivas M. Synthesis of imidazole, Coumarine and isoxazole containing new triheterocyclic compounds and their derivatives. *Ind J Chem* 2004;44B:563-7.
11. Nitin N, Agrawal, Soni PA. Synthesis of pyrazole and isoxazole in triethanolamine medium. *Ind J Chem* 2005;46B:532-4.
12. Sureshbabu D, Jianping Xu, Ashton T, Hamme II. Isoxazoles from 1,1 Disubstituted Bromoalkene. *Tetrahedron Lett* 2007;48(7):1295-8.
13. Vijay KT, Narasimha G, Raga B, Rajendra P. Synthesis, Characterization and Biological Activities of Some New Pyrimidines and Isoxazoles bearing Benzofuran moiety. *Int J Chem Tech Res* 2010;2:1434-40.
14. Madhavi K, Bharathi K, Prasad K. Synthesis and evaluation of 3-methyl-4-nitro-5-(substitutedstyryl) isoxazoles for antioxidant and anti-inflammatory activities. *Res J Pharm Biolo Chem Sci* 2010;1(4):1073.
15. Kapubalu SK, Kovvuri TR, Gudaparthi O, Dubey PK. Synthesis and characterization of some novel isoxazole via chalcone intermediate. *Der Pharma Chemica* 2011;3(5):113-22.
16. Leonardo DN, Paola V, Antonio S, Stefania T, Patrignani P. Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal Cyclooxygenase-2 selectivity by

- sulfonamide group removal. *J Med Chem* 2004;47:4881-90.
17. John JT, David LB, Jeffery SC, Matthew JG, Carol MK. 4-[5-methyl-3-phenylisoxazol-4-yl]-benzene sulfonamide, Valdecoxib: A potent and selective inhibitor of COX-2. *J Med Chem* 2000;43:775-7.
  18. Kachhadia VV, Patel MR, Joshi HS. Synthesis of Isoxazoles and Cyanopyridines Bearing Benzo(b)thiophene Nucleus as Potential Antitubercular and Antimicrobial Agents. *J Sci Islamic Rep Iran* 2004; 15(1):47-51.
  19. Rajendra PY, Rajasekhar KK, Shankarananth V, Pradeep kumar GSS, Harish reddy G, Rajeev Reddy B. Synthesis and antimicrobial activity of 3,5-diaryl isoxazole derivatives. *J Pharm Res* 2010;3(11):2769-71.
  20. Dravyakar BR, Kawade DP, Khedekar PB, Bhusari KP. Design and syntheses some new diphenylaminoisoxazolines as potent anti-inflammatory agent. *Ind J Chem* 2008;47B:1559-67.
  21. Rajanarendar E, Mohan G, Shiva Rami Reddy A. Synthesis and some anti-microbial activity of new isoxazolyl-1,3-benzoxazines. *Ind J Chem* 2008;47B:112-6.
  22. Chakka G, Rama rao N, Laxmi K, Ramkrishna R. microwave assisted synthesis of some new 3-(4-substituted aniline)-5-(3-4-disubstituted aryl)-2-isoxazole as potential anthelmintic agent. *J Glob Pharma sci* 2011;1(1):26-41
  23. Rajesh S, jaishree V, Ramesh B, Sachin P. Cytotoxic study of 3-(1-benzofuran-2-yl)-5-(substituted aryl) isoxazole. *Int J Pharma sci* 2011;2(1):115-21.
  24. Harsha Mohan. Essential pathology for dental students. New Delhi: Jaypee Brothers medical publishers;2007:95-115.
  25. Ilango K, Valentina P. Text book of Medicinal Chemistry Vol-1. Chennai: Keerthi Publishers;2007:336-52.
  26. Sathish NK, Ravitejha P, Ramkrishna S, Chethan I. Synthesis, characterisation and anti-inflammatory activity of some novel isoxazole. *Der Pharmacia lett* 2011;3(3):378-82.
  27. Bhausahab M, Vijay B, Baliram B. Synthesis and antimicrobial activity of isoxazole. *Der Chemi Sini* 2011;2(5):147-51.
  28. Rajgopal HU, Sanath KG, Himabindu V. Synthesis, antimicrobial and anti-inflammatory studies of isoxazole analogues of rosuvastatin. *Der Pharma Chemica* 2011;3(3):39-50.
  29. Banerjee M, Sudeep Kumar HK, Sahu SK, Das A. Synthesis and In-vitro protein denaturation screening of novel substituted isoxazole/pyrazole derivatives. *Rasa J Chem* 2011;4(2):413-7.
  30. Karabasanagouda T, Girisha M, Vasudeva A. Synthesis of some new pyrazolines and isoxazole carrying 4-methylthiophenyl moiety as potential analgesic and anti-inflammatory agents. *Ind J Chem* 2009;48(B):430-7.
  31. Manju SV, Harsha K, Deepthi D, Francis S. Synthesis and charectaristion of novel isoxazoliny(1,2,4) triazino indole derivatives and evaluation of their anti-inflammatory and anticonvulsant activites. *Int J B Drug Res* 2008;1(1):100-6.
  32. Bhaskar VH, Mohite PB. Synthesis, characterisation and evaluation of anticancer activity of some tetrazole derivatives. *J Opt Biomed Mat* 2010;2(4):249-59.
  33. Parmar KA, Prajapati SN, Joshi SA, Goswami KV. Studies on cynopyridones and isoxazoles ring system in the synthesis of novel bioactive compounds. *Der Chemica sini* 2011;2(1):100-10.
  34. Nagwa MMH, Essam MS. Synthesis and antimicrobial evaluation of some heterocyclic chalcone derivatives. *Mole* 2011;16:2304-12.
  35. Rajput AP, Girase PD. Synthesis, characterisation and microbial screening of isoxazole derivatives of 2,6-dichloro-1-(N-substituted phenyl)-1,4-dihydropyridine-3,5-dicarbaldehyde. *Int J Chem res* 2011;2(4):0976-5689.
  36. Yoon-suk lee, Sun Min P, Byeang K. Synthesis of 5-isoxazol-5-yl-2'-deoxy uredines exhibiting anti-viral activity. *Bioorg Med Chem Lett* 2009;19:1126-8
  37. Jae Seok L, Yong SC, Moon HC, Yeong HK, Chung BY. Synthesis and *in vitro* activity of novel isoxazolyl tetrahydropyridinyl oxazolidinone anti-bacterial agents. *Bioorg Med Chem Lett* 2003;13:4117-20.
  38. Kachhadia VV, Patel MR, Joshi HS. Synthesis of isoxazoles and cyanopyridines bearing benzo thiophene nucleus as potential anti-tubercular and anti-microbial agents. *J sci Islamic Rep Iran* 2004;14:47-51.
  39. Naohiko Y, Hisao I, Yukio S. Synthesis and anti-bacterial activity of triazole and isoxazole derivatives of ampicillin. *J Anti-bio* 1983;1516-24.
  40. Yoon SL, Byeang HK. Heterocyclic nucleoside analogues: design and synthesis of antiviral, modified nucleosides containing isoxazoles heterocycles. *Bioorg. Med Chem Lett* 2002;12:1395-7.
  41. Sahu SK, Banerjee M, Sahu D, Behera CC, Pradhan GC. Synthesis, analgesic and anti-microbial activities of some novel isoxazoles derivatives. Dhaka University. *J Pharm Sci* 2008;7(2):113-8.
  42. George BM, Thomas RD, Jefffrey TM, Stanely DA, Richard K. Studies on anti-fungal agents. Novel 3, 5-diphenyl-3-(1H-imidazol-1-ylmethyl)-2-alkylisoxazolidine derivatives. *J Med Chem* 1988;31:2008-14.
  43. Erick F, Jens P, Bente F, Brigitte S, Anders B. Selective inhibitors of glial GABA uptake: synthesis, absolute stereochemistry, and pharmacology of the enantiomers of 3-hydroxy-4-amino-4,5,6,7-tetrahydro-1, 2-benzisoxazole (exo-THPO) and analogues. *J Med Chem* 1999;42:5402-14.
  44. Amgad GH, Praveen rao PN, Edward EK. Design and synthesis of 4,5-diphenyl-4-isoxazolines: novel inhibitors of cyclooxygenase -2 with analgesic and anti-inflammatory activity. *J Med Chem* 2001;44:2921-7.
  45. Hasse K, Frank AS, Rine BS, Hans BO, Madsen U. Selective antagonists at group I metabotropic glutamate receptors: synthesis and molecular pharmacology of 4-aryl-3-isoxazolol amino acids. *J Med Chem* 2002;45:988-91.
  46. Hisashi S, Syoji O, Tanaka M, Shibata T, Iwao M. Isoxazolidine-3,5-dione and noncyclic 1,3 dicarbonyl compound as hypoglycaemic agents. *J Med Chem* 1998;41:1927-33.
  47. Nicholas RN, Mark ER, Richard S, David JT, Aleta R. Lipophilic 4-isoxazolyl-1,4-dihydropyridines: synthesis and structure- activity relationships. *J Med Chem* 1999;42:3087-93.
  48. Joseph PY, James SN, Smith DW, Walter GL, John DC. Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl) - and (1,2-benzisoxazol-3-yl-) piperazine derivatives as potential anti-psychotic agents. *J Med Chem* 1986;29:359-69.
  49. Hariharan S, Mathur HH, Trivedi GK. Synthesis of polynuclear heterocyclic compounds: part-I synthesis of [1] benzopyrano [4, 3-d] isoxazoles via nitronc cyclo addition. *Ind J Chem* 1988;47B:994-6.
  50. Donato D, Stefania F, Fabio P, Riccardo RP, Mauro FA. Photoreaction of some 5-alkyldene -2,5-dihydroisoxazoles:

- facile construction of novel unclassical  $\beta$ -lactam containing heterocycles. *Tetrahedron Lett* 2007;63:1583-8.
51. Jane EM, Mark WD, Katharine MG, Robert AJW, Joesph PAH. Investigation of the scope of a [3+2] cycloaddition approach to isoxazole boronic esters. *Tetrahedron Lett* 2005;61:6707-14.
  52. Chiacchio U, Antonino C, Giuseppe G, Venerado P, Antonio R. Stereoselective synthesis of isoxazole and pyrazole annulated sultams via intermolecular 1,3-dipolar cycloaddition reactions. *Tetrahedron Lett* 1997;53(40):13855-66.
  53. Rajanarendar E, Firoz PS, Siva Rami reddy A. Synthesis of novel isoxazolyl 1,3,5-benzoxadiazocine-4-thiones as possible biodynamic agents. *Ind J Chem* 2008;47B:1753-8.
  54. Venkateswarlu P, Srinivas B. Synthesis and characterization of new isoxazoles derived from benzosuberones. *Ind J Chem* 2006;47B:1753-5.
  55. Suresh babu D, Jianping X, Ashton T, Hamme H. Isoxazoles from 1,1-disubstituted bromoalkenes. *Tetrahedron Lett* 2007;48:1295-8.
  56. Evdoxia CA, Pygmalion L, Marigoula M, Anestis G, Joanna N. 1,3-dipolar cycloaddition approach to isoxazole, isoxazoline and isoxazolidine analogues of C-nucleosides related to pseudouridine. *Tetrahedron Lett* 2006;62:1494-1501.